SolasCure, a Cambridge, UK-based biotech startup, raised £1.2m in funding.
Seneca Partners invested:
- £733k invested via Seneca EIS Portfolio Service, and
- £500K via Seneca Growth Capital VCT.
The company intends to use the funds for the further development of its wound cleaning product, Aurase®.
Led by Dr. Sam Bakri, Executive Chairman and CEO, SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Its first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.